CHE
CHE
Chemed CorporationIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $639.34M ▲ | $105.5M ▼ | $76.75M ▲ | 12% ▲ | $5.48 ▲ | $122.3M ▲ |
| Q3-2025 | $624.9M ▲ | $105.78M ▼ | $64.24M ▲ | 10.28% ▲ | $4.46 ▲ | $101.78M ▲ |
| Q2-2025 | $618.8M ▼ | $116.61M ▼ | $52.49M ▼ | 8.48% ▼ | $3.6 ▼ | $87.82M ▼ |
| Q1-2025 | $646.94M ▲ | $121.66M ▲ | $71.76M ▼ | 11.09% ▼ | $4.91 ▼ | $112.02M ▼ |
| Q4-2024 | $639.99M | $120.24M | $90.32M | 14.11% | $6.08 | $136.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $74.52M ▼ | $1.64B ▲ | $660.61M ▲ | $979.4M ▼ |
| Q3-2025 | $129.75M ▼ | $1.62B ▼ | $546.94M ▲ | $1.08B ▼ |
| Q2-2025 | $249.9M ▲ | $1.72B ▼ | $519.36M ▼ | $1.2B ▲ |
| Q1-2025 | $173.88M ▼ | $1.73B ▲ | $544.75M ▼ | $1.18B ▲ |
| Q4-2024 | $178.35M | $1.67B | $549.58M | $1.12B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $76.75M ▲ | $133.53M ▲ | $-15.95M ▼ | $-172.82M ▲ | $-55.24M ▲ | $117.19M ▲ |
| Q3-2025 | $64.24M ▲ | $83.39M ▼ | $-14.23M ▲ | $-189.31M ▼ | $-120.15M ▼ | $66.03M ▼ |
| Q2-2025 | $52.49M ▼ | $138.61M ▲ | $-15.48M ▼ | $-47.1M ▼ | $76.02M ▲ | $122.8M ▲ |
| Q1-2025 | $71.76M ▼ | $32.74M ▼ | $-13.67M ▼ | $-23.54M ▲ | $-4.47M ▲ | $19.46M ▼ |
| Q4-2024 | $90.32M | $164.91M | $-12.52M | $-212.49M | $-60.1M | $152.15M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
Segment Roto Rooter | $250.00M ▲ | $230.00M ▼ | $230.00M ▲ | $230.00M ▲ |
Segment Vitas | $420.00M ▲ | $420.00M ▲ | $420.00M ▲ | $430.00M ▲ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Chemed Corporation's financial evolution and strategic trajectory over the past five years.
Chemed combines strong profitability, robust cash generation, and a conservative balance sheet with leadership positions in two essential service markets. The business benefits from scale, brand strength, and operational expertise, particularly in regulated hospice care and time‑sensitive plumbing services. Liquidity and leverage are well managed, free cash flow is ample, and ongoing technology and process innovations support service quality and efficiency.
Key risks center on regulatory and reimbursement exposure in hospice, labor cost and availability in healthcare, and the inherently fragmented, locally competitive nature of the plumbing and home services market. The balance sheet’s heavy reliance on goodwill and intangible assets introduces potential impairment risk if acquired businesses underperform. Aggressive capital returns via buybacks and dividends also reduce the cash buffer, making ongoing performance and cash generation critical.
Based on the available information, Chemed appears positioned for steady performance, supported by defensive, needs‑based demand in hospice and recurring service needs in plumbing and restoration. Future results will likely depend on how well the company manages regulatory and labor headwinds, continues integrating technology and analytics into both businesses, and balances shareholder returns with maintaining financial flexibility. With only one year of detailed financial data, visibility into long‑term trends is limited, but the current snapshot suggests a mature, well‑run company with clear competitive advantages and manageable, though meaningful, external risks.
About Chemed Corporation
https://www.chemed.comChemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $639.34M ▲ | $105.5M ▼ | $76.75M ▲ | 12% ▲ | $5.48 ▲ | $122.3M ▲ |
| Q3-2025 | $624.9M ▲ | $105.78M ▼ | $64.24M ▲ | 10.28% ▲ | $4.46 ▲ | $101.78M ▲ |
| Q2-2025 | $618.8M ▼ | $116.61M ▼ | $52.49M ▼ | 8.48% ▼ | $3.6 ▼ | $87.82M ▼ |
| Q1-2025 | $646.94M ▲ | $121.66M ▲ | $71.76M ▼ | 11.09% ▼ | $4.91 ▼ | $112.02M ▼ |
| Q4-2024 | $639.99M | $120.24M | $90.32M | 14.11% | $6.08 | $136.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $74.52M ▼ | $1.64B ▲ | $660.61M ▲ | $979.4M ▼ |
| Q3-2025 | $129.75M ▼ | $1.62B ▼ | $546.94M ▲ | $1.08B ▼ |
| Q2-2025 | $249.9M ▲ | $1.72B ▼ | $519.36M ▼ | $1.2B ▲ |
| Q1-2025 | $173.88M ▼ | $1.73B ▲ | $544.75M ▼ | $1.18B ▲ |
| Q4-2024 | $178.35M | $1.67B | $549.58M | $1.12B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $76.75M ▲ | $133.53M ▲ | $-15.95M ▼ | $-172.82M ▲ | $-55.24M ▲ | $117.19M ▲ |
| Q3-2025 | $64.24M ▲ | $83.39M ▼ | $-14.23M ▲ | $-189.31M ▼ | $-120.15M ▼ | $66.03M ▼ |
| Q2-2025 | $52.49M ▼ | $138.61M ▲ | $-15.48M ▼ | $-47.1M ▼ | $76.02M ▲ | $122.8M ▲ |
| Q1-2025 | $71.76M ▼ | $32.74M ▼ | $-13.67M ▼ | $-23.54M ▲ | $-4.47M ▲ | $19.46M ▼ |
| Q4-2024 | $90.32M | $164.91M | $-12.52M | $-212.49M | $-60.1M | $152.15M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
Segment Roto Rooter | $250.00M ▲ | $230.00M ▼ | $230.00M ▲ | $230.00M ▲ |
Segment Vitas | $420.00M ▲ | $420.00M ▲ | $420.00M ▲ | $430.00M ▲ |
Q4 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Chemed Corporation's financial evolution and strategic trajectory over the past five years.
Chemed combines strong profitability, robust cash generation, and a conservative balance sheet with leadership positions in two essential service markets. The business benefits from scale, brand strength, and operational expertise, particularly in regulated hospice care and time‑sensitive plumbing services. Liquidity and leverage are well managed, free cash flow is ample, and ongoing technology and process innovations support service quality and efficiency.
Key risks center on regulatory and reimbursement exposure in hospice, labor cost and availability in healthcare, and the inherently fragmented, locally competitive nature of the plumbing and home services market. The balance sheet’s heavy reliance on goodwill and intangible assets introduces potential impairment risk if acquired businesses underperform. Aggressive capital returns via buybacks and dividends also reduce the cash buffer, making ongoing performance and cash generation critical.
Based on the available information, Chemed appears positioned for steady performance, supported by defensive, needs‑based demand in hospice and recurring service needs in plumbing and restoration. Future results will likely depend on how well the company manages regulatory and labor headwinds, continues integrating technology and analytics into both businesses, and balances shareholder returns with maintaining financial flexibility. With only one year of detailed financial data, visibility into long‑term trends is limited, but the current snapshot suggests a mature, well‑run company with clear competitive advantages and manageable, though meaningful, external risks.

CEO
Kevin J. McNamara
Compensation Summary
(Year 2023)
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2005-05-12 | Forward | 2:1 |
| 1981-11-12 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 268
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
METATRON CAPITAL SICAV PLC
Shares:15.4M
Value:$5.94B
VANGUARD GROUP INC
Shares:1.54M
Value:$593.5M
BLACKROCK INC.
Shares:1.44M
Value:$555.62M
Summary
Showing Top 3 of 738

